ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt

详细信息    查看全文

• 作者：Amira B. Kassem^a ; ^b ; ; Salem Eid Salem^c ; Mohamed E. Abdelrahim^d ; Amira S.A. Said^a ; Ahmad Salahuddin^e ; Marwa Mahmoud Hussein^c ; Abeer A. Bahnassy^f
• 关键词：ERCC1 ; ERCC2 ; CRC ; Oxaliplatin ; Survival
• 刊名：Experimental and Molecular Pathology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：102
• 期：1
• 页码：78-85
• 全文大小：868 K
• 卷排序：102

文摘

The impact of Excision repair cross-complementation group 1 (ERCC1) and group 2 (ERCC2) expression levels on the efficacy of oxaliplatin-based chemotherapy is still controversial. The present study was conducted to determine the predictive value of these molecular biomarkers in stage III and IV colorectal cancer (CRC) patients receiving oxaliplatin (OX)-based chemotherapy as first-line treatment.MethodsThe study included 80 CRC patients who received first line oxaliplatin based chemotherapy The expression levels of ERCC1 and ERCC2-mRNA and proteins were determined in the primary tumors by quantitative real time reverse transcription polymerase chain reaction(RT-qPCR) and immunohistochemistry (IHC); respectively. The results of mRNA expression were correlated with patients' characteristics, response to treatment, overall- and event free survival (OS & EFS).ResultsSixty four out of the 80 patients were legible for assessment of ERCC1 and ERCC2 expression. The cut-off levels of ERCC1and ERCC2-RNA were 3.8 × 10− 3& 4.6 × 10− 3; respectively. Reduced ERCC1 and ERCC2 RNA expressions were detected in 50 (78.1%) and 48 (75%) cases, respectively whereas reduced proteins were detected in 48 cases (75%) for ERCC1 and ERCC2. After The median follow up period was 30.5 months (range: 7–104 months), Patients with low mRNAERCC1levels showed significantly longer OS (p = 0.011) and EFS (p ˂ 0.001). However, no significant relation was found between ERCC2 levels and OS or EFS. In multivariate analysis performance status (PS), stage of the disease and ERCC1-mRNA expression were independent prognostic factors for EFS whereas tumor histology and stage of the disease were independent factors for OS.ConclusionsERCC1 expression levels may help in selecting patients who benefit from oxaliplatin chemotherapy in stage III & IV CRC. Further large trials are needed to validate these data.